In a report released today, Chris Shibutani from Cowen & Co. maintained a Buy rating on Kura Oncology (NASDAQ: KURA). The company’s shares opened today at $15.70.
According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 13.0% and a 41.5% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Pieris Pharmaceuticals, and Nektar Therapeutics.
Currently, the analyst consensus on Kura Oncology is Strong Buy and the average price target is $27.50, representing a 75.2% upside.
In a report issued on May 2, Oppenheimer also assigned a Buy rating to the stock with a $27 price target.
See today’s analyst top recommended stocks >>
Based on Kura Oncology’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $10.75 million. In comparison, last year the company had a GAAP net loss of $7.53 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.
